|
1
|
American Cancer Society: Key statistics
for prostate cancer. Prostate Cancer Facts. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
|
|
2
|
Kume H, Kawai T, Nagata M, Azuma T,
Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H and Homma
Y: Intermittent docetaxel chemotherapy is feasible for
castration-resistant prostate cancer. Mol Clin Oncol. 3:303–307.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kharaziha P, Chioureas D, Rutishauser D,
Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev
R, Ullén A, et al: Molecular profiling of prostate cancer derived
exosomes may reveal a predictive signature for response to
docetaxel. Oncotarget. 6:21740–21754. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Newton AC: Protein kinase C: Poised to
signal. Am J Physiol Endocrinol Metab. 298:E395–E402. 2010.
View Article : Google Scholar :
|
|
5
|
Nishizuka Y: Intracellular signaling by
hydrolysis of phospholipids and activation of protein kinase C.
Science. 258:607–614. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Selbie LA, Schmitz-Peiffer C, Sheng Y and
Biden TJ: Molecular cloning and characterization of PKC iota, an
atypical isoform of protein kinase C derived from insulin-secreting
cells. J Biol Chem. 268:24296–24302. 1993.PubMed/NCBI
|
|
7
|
Hirai T, Niino YS and Chida K: PKC zeta
II, a small molecule of protein kinase C zeta, specifically
expressed in the mouse brain. Neurosci Lett. 348:151–154. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayashi A, Seki N, Hattori A, Kozuma S and
Saito T: PKCnu, a new member of the protein kinase C family,
composes a fourth subfamily with PKCmu. Biochim Biophys Acta.
1450:99–106. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Persons DA, Wilkison WO, Bell RM and Finn
OJ: Altered growth regulation and enhanced tumorigenicity of NIH
3T3 fibroblasts transfected with protein kinase C-I cDNA. Cell.
52:447–458. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Housey GM, Johnson MD, Hsiao WL, O’Brian
CA, Murphy JP, Kirschmeier P and Weinstein IB: Overproduction of
protein kinase C causes disordered growth control in rat
fibroblasts. Cell. 52:343–354. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kamata T, Sullivan NF and Wooten MW:
Reduced protein kinase C activity in a ras-resistant cell line
derived from Ki-MSV transformed cells. Oncogene. 1:37–46.
1987.PubMed/NCBI
|
|
12
|
Weyman CM, Taparowsky EJ, Wolfson M and
Ashendel CL: Partial down-regulation of protein kinase C in C3H 10T
1/2 mouse fibroblasts transfected with the human Ha-ras oncogene.
Cancer Res. 48:6535–6541. 1988.PubMed/NCBI
|
|
13
|
Mizuguchi J, Nakabayashi H, Yoshida Y,
Huang KP, Uchida T, Sasaki T, Ohno S and Suzuki K: Increased
degradation of protein kinase C without diminution of mRNA level
after treatment of WEHI-231 B lymphoma cells with phorbol esters.
Biochem Biophys Res Commun. 155:1311–1317. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hudes GR: Signaling inhibitors in the
treatment of prostate cancer. Invest New Drugs. 20:159–172. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu D, Thakore CU, Wescott GG, McCubrey JA
and Terrian DM: Integrin signaling links protein kinase Cepsilon to
the protein kinase B/Akt survival pathway in recurrent prostate
cancer cells. Oncogene. 23:8659–8672. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rusnak JM and Lazo JS: Downregulation of
protein kinase C suppresses induction of apoptosis in human
prostatic carcinoma cells. Exp Cell Res. 224:189–199. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jaggi M, Rao PS, Smith DJ, Hemstreet GP
and Balaji KC: Protein kinase C mu is down-regulated in
androgen-independent prostate cancer. Biochem Biophys Res Commun.
307:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rao PS, Jaggi M, Smith DJ, Hemstreet GP
and Balaji KC: Metallothionein 2A interacts with the kinase domain
of PKCmu in prostate cancer. Biochem Biophys Res Commun.
310:1032–1038. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inoue T, Yoshida T, Shimizu Y, Kobayashi
T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E and Ogawa O:
Requirement of androgen-dependent activation of protein kinase
Czeta for androgen-dependent cell proliferation in LNCaP Cells and
its roles in transition to androgen-independent cells. Mol
Endocrinol. 20:3053–3069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Regala RP, Weems C, Jamieson L, Copland
JA, Thompson EA and Fields AP: Atypical protein kinase Ciota plays
a critical role in human lung cancer cell growth and
tumorigenicity. J Biol Chem. 280:31109–31115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weichert W, Gekeler V, Denkert C, Dietel M
and Hauptmann S: Protein kinase C isoform expression in ovarian
carcinoma correlates with indicators of poor prognosis. Int J
Oncol. 23:633–639. 2003.PubMed/NCBI
|
|
22
|
Win HY and Acevedo-Duncan M: Atypical
protein kinase C phosphorylates IKKalphabeta in transformed
non-malignant and malignant prostate cell survival. Cancer Lett.
270:302–311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Regala RP, Weems C, Jamieson L, Khoor A,
Edell ES, Lohse CM and Fields AP: Atypical protein kinase C iota is
an oncogene in human non-small cell lung cancer. Cancer Res.
65:8905–8911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Desai S, Pillai P, Win-Piazza H and
Acevedo-Duncan M: PKC-ι promotes glioblastoma cell survival by
phosphorylating and inhibiting BAD through a phosphatidylinositol
3-kinase pathway. Biochim Biophys Acta. 1813.1190–1197. 2011.
|
|
25
|
Pillai P, Desai S, Patel R, Sajan M,
Farese R, Ostrov D and Acevedo-Duncan M: A novel PKC-ι inhibitor
abrogates cell proliferation and induces apoptosis in
neuroblastoma. Int J Biochem Cell Biol. 43:784–794. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications.
1979.Biotechnology. 24:145–149. 1992.
|
|
29
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
30
|
Ratnayake WS, Apostolatos AH, Ostrov DA
and Acevedo- Duncan M: Two novel atypical PKC inhibitors; ACPD and
DNDA effectively mitigate cell proliferation and epithelial to
mesenchymal transition of metastatic melanoma while inducing
apoptosis. Int J Oncol. 51:1370–1382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Diaz-Meco MT, Municio MM, Sanchez P,
Lozano J and Moscat J: Lambda-interacting protein, a novel protein
that specifically interacts with the zinc finger domain of the
atypical protein kinase C isotype lambda/iota and stimulates its
kinase activity in vitro and in vivo. Mol Cell Biol. 16:105–114.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eder AM, Sui X, Rosen DG, Nolden LK, Cheng
KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, et al:
Atypical PKCiota contributes to poor prognosis through loss of
apical-basal polarity and cyclin E overexpression in ovarian
cancer. Proc Natl Acad Sci USA. 102:12519–12524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Selzer E, Okamoto I, Lucas T, Kodym R,
Pehamberger H and Jansen B: Protein kinase C isoforms in normal and
transformed cells of the melanocytic lineage. Melanoma Res.
12:201–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Q, Wang J-M, Liu C, Xiao B-L, Lu J-X
and Zou S-Q: Correlation of aPKC-iota and E-cadherin expression
with invasion and prognosis of cholangiocarcinoma. Hepatobiliary
Pancreat Dis Int. 7:70–75. 2008.PubMed/NCBI
|
|
35
|
Patel R, Win H, Desai S, Patel K, Matthews
JA and Acevedo- Duncan M: Involvement of PKC-iota in glioma
proliferation. Cell Prolif. 41:122–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang Y-L, Chu J-Y, Luo M-L, Wu YP, Zhang
Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, et al: Amplification of
PRKCI, located in 3q26, is associated with lymph node metastasis in
esophageal squamous cell carcinoma. Genes Chromosomes Cancer.
47:127–136. 2008. View Article : Google Scholar
|
|
37
|
Justilien V, Walsh MP, Ali SA, Thompson
EA, Murray NR and Fields AP: The PRKCI and SOX2 oncogenes are
coamplified and cooperate to activate Hedgehog signaling in lung
squamous cell carcinoma. Cancer Cell. 25:139–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim S-W, Schifano M, Oleksyn D, Jordan CT,
Ryan D, Insel R, Zhao J and Chen L: Protein kinase C-associated
kinase regulates NF-κB activation through inducing IKK activation.
Int J Oncol. 45:1707–1714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie J, Guo Q, Zhu H, Wooten MW and Mattson
MP: Protein kinase C iota protects neural cells against apoptosis
induced by amyloid beta-peptide. Brain Res Mol Brain Res.
82:107–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
